ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML

Centre Hospitalier Universitaire de Nice

Status: Not yet enrolling

Conditions: Leukemia, Myeloid

Treatments: Other: Middle Eastern or North Coast of Africa patients with newly AML

Study type: Observational

Funder types: Other

Identifiers

NCT06512610

24Hemato02

Details and patient eligibility

About

"In daily clinical practice, 2022 ELN guidelines were used to predict response to conventional treatment and to guide the need for allogenic stem cell transplantation. But, the team has to underline that ELN guidelines are mainly reflective of relatively young Caucasian patients. Few studies have compared 2017 and 2022 ELN in ethnicity cohorts to evaluate the potential prognostic value of this new criteria in these types of population. For example, with the 2022 ELN guidelines, the disease-free surviva) and the overall survival of African American < 60 y.o were not statistically different between intermediate and adverse groups (p=0.30, p=0,46). There were not a significant difference between favorable and intermediate groups in DFS (p=0.42, p=0.42) respectively in African American and Hispanic patients or in OS (p=0.67) in Hispanic patients. Is the 2022 ELN applicable to all ethnic subgroups? To date, no studies have examined and validated its applicability in Middle Eastern or North Coast of Africa (MENAFC) patients."

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnosed AML
• At least 18 yo
• MENAFC (Middle East ern of North Coast of Africa) patients with HLA HLA > 50%
• ECOG performance status of 0,1,2,3"

Exclusion criteria

• Acute promyelocytic leukemia
• Patients alive at the start of the study who did not receive study information or who objected to the collection of data"

Trial design

100 participants in 1 patient group

Middle Eastern or North Coast of Africa patients with newly AML

Description:

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia in MENAFC patients

Treatment:

Other: Middle Eastern or North Coast of Africa patients with newly AML